ACRS News and Press, Aclaris Therapeutics Inc. From 03/14/24

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Rec...

2024-03-14 08:45:28 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2024 – USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all m...

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and ...

2024-01-22 17:55:10 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris spikes after leadership change, strategic review Aclaris draws second downgrade despite Phase 2 win for eczema therapy Seeking Al...

2024-01-22 08:37:55 ET Rail Vision  ( RVSN ) +96% Successfully Secures Approval and Certifications and for EU Railway Standards. Nustar Energy ( NS ) +23% to buy NuStar in all-stock deal valued at $7.3B. MSP Recovery  ( LIFW ) +23% . North...

2024-01-16 08:58:06 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris draws second downgrade despite Phase 2 win for eczema therapy Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy ...

- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer - WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ...

2024-01-11 13:30:02 ET Stifel Nicolaus analyst issues BUY recommendation for ACRS on January 11, 2024 02:00PM ET. The previous analyst recommendation was Buy. ACRS was trading at $0.9751 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

2024-01-11 07:53:52 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy Aclaris posts topline data from mid-stage trial for eczema therapy ...

2024-01-10 15:09:26 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris posts topline data from mid-stage trial for eczema therapy Aclaris to slash 46% of workforce as it reprioritizes drug programs Se...